Stock Comparison

ABBV vs MYO

AbbVie Inc vs Myomo Inc

The Verdict

MYO takes this one.

ABBV

AbbVie Inc

0.1

out of 10

Distressed

Winner

MYO

Myomo Inc

6.0

out of 10

Solid Pick

Head-to-Head

$381.1B

Market Cap

$54M

104.8

P/E Ratio

-3.8

5.8%

Profit Margin

-36.7%

95.6%

Return on Equity

-114.9%

20.2

Debt-to-Equity

1.0

Moderate

Overall Risk

Aggressive

0.1

DVR Score

6.0

The Deep Dive

ABBV0.1/10

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Full ABBV Analysis

MYO6.0/10

Myomo continues to address a large, underserved neurological rehabilitation market with its MyoPro device, validated by strong regulatory clearances and expanding reimbursement. Q1 2026 results, reported on May 9, 2026, exceeded consensus estimates with $10.1M revenue and narrower EPS loss of ($0.07), building on previous operational improvements. The formalization of Horton Capital's 6.0% stake a...

Full MYO Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.